This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Potassium triiodide
- DrugBank Accession Number
- DB14492
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Potassium triiodide (DB14492)
- Weight
- Average: 419.8117
Monoisotopic: 419.67712 - Chemical Formula
- I3K
- Synonyms
- Iodine aqueous
- Lugol's iodine
- Lugol's solution
- Microiodide
- Potassium triiodide
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcebutolol Potassium triiodide may increase the hyperkalemic activities of Acebutolol. Aceclofenac Potassium triiodide may increase the hyperkalemic activities of Aceclofenac. Acemetacin Potassium triiodide may increase the hyperkalemic activities of Acemetacin. Acetylsalicylic acid Potassium triiodide may increase the hyperkalemic activities of Acetylsalicylic acid. Alclofenac Potassium triiodide may increase the hyperkalemic activities of Alclofenac. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- International/Other Brands
- Lugol's solution
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image CitraNatal 90 DHA Potassium triiodide (150 ug/1) + Ascorbic acid (120 mg/1) + Calcium citrate tetrahydrate (160 mg/1) + Cupric oxide (2 mg/1) + Docusate sodium (50 mg/1) + Folic acid (1 mg/1) + Iron (90 mg/1) + Nicotinamide (20 mg/1) + Pyridoxine hydrochloride (20 mg/1) + Riboprine (3.4 mg/1) + Thiamine chloride (3 mg/1) + Vitamin D (400 [iU]/1) + Zinc oxide (25 mg/1) + alpha-Tocopherol acetate (30 [iU]/1) Tablet Oral Mission Pharmacal 2010-02-01 Not applicable US 
- Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image CitraNatal 90 DHA Potassium triiodide (150 ug/1) + Ascorbic acid (120 mg/1) + Calcium citrate tetrahydrate (160 mg/1) + Cupric oxide (2 mg/1) + Docusate sodium (50 mg/1) + Folic acid (1 mg/1) + Iron (90 mg/1) + Nicotinamide (20 mg/1) + Pyridoxine hydrochloride (20 mg/1) + Riboprine (3.4 mg/1) + Thiamine chloride (3 mg/1) + Vitamin D (400 [iU]/1) + Zinc oxide (25 mg/1) + alpha-Tocopherol acetate (30 [iU]/1) Tablet Oral Mission Pharmacal 2010-02-01 Not applicable US
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- T66M6Y3KSA
- CAS number
- 12298-68-9
- InChI Key
- DKNPRRRKHAEUMW-UHFFFAOYSA-N
- InChI
- InChI=1S/I3.K/c1-3-2;/q-1;+1
- IUPAC Name
- potassium triiodan-2-uide
- SMILES
- [K+].I[I-]I
References
- General References
- Not Available
- External Links
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Unknown Status Diagnostic Endoscopists'Subjective Assessments / Image Quality of Early Esophageal Squamous Neoplasia 1 3 Recruiting Treatment Hyperthyroidism 1 3 Terminated Prevention Heart Failure 1 2 Completed Screening Image Quality / Irritation of the Mucous Membranes 1 2 Terminated Treatment Non-Hodgkin's Lymphoma (NHL) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP 2.04 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 0 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 0 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 40.02 m3·mol-1 Chemaxon Polarizability 16.55 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at July 09, 2018 19:43 / Updated at June 12, 2020 16:53